Cabaletta Bio (CABA) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed Cabaletta Bio (CABA) over the past year, losing 15.2% versus a loss of 19.1%. Over five years, CABA leads with a -84.1% price change compared with -98.1% for XFOR. Cabaletta Bio is the larger company by market cap ($327.2 million vs $288.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | XFOR |
|---|---|---|
| Share price | $1.93 | $2.91 |
| Market cap | $327.22M | $288.52M |
| 1-day change | -1.03% | +4.30% |
| YTD return | -10.96% | -27.25% |
| 1-year return | -19.09% | -15.16% |
| 5-year return | -84.09% | -98.15% |
| P/E ratio (TTM) | — | 145.50 |
| EPS (TTM) | $-1.49 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.23 | $4.83 |
| 52-week low | $1.83 | $2.70 |
| Distance from 52-week high | -54.37% | -39.75% |
| Analyst consensus | none | none |
| Avg. price target upside | +586.53% | +298.63% |
| Average volume | 4.64M | 848.49K |
| Shares outstanding | 169.55M | 99.15M |
| Employees | 154 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
CABA vs XFOR FAQ
Which is bigger, Cabaletta Bio or X4 Pharmaceuticals?
Cabaletta Bio (CABA) is larger, with a market capitalization of $327.22M compared with $288.52M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, CABA or XFOR?
XFOR returned -15.16% over the past 12 months, compared with -19.09% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.